Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | integrin alpha-V |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6468H10008N1744O2006S40 |
Molar mass | 145579.81 g·mol−1 |
![]() ![]() |
Intetumumab is a human monoclonal antibody targeting integrins[1] that was being studied for the treatment of solid tumors.[2]
Intetumumab was developed by Centocor, Inc.
Phase II clinical trials for treatment of melanoma and prostate cancer were in progress when development of the drug was discontinued.[3]
References
- ^ Łasiñska I, Mackiewicz J (2019). "Integrins as A New Target for Cancer Treatment". Anti-Cancer Agents in Medicinal Chemistry. 19 (5): 580–586. doi:10.2174/1871520618666181119103413. PMID 30451118. S2CID 53952455.
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Intetumumab" (PDF). American Medical Association.
- ^ "Intetumumab". AdisInsight. Retrieved 30 January 2017.